◆英語タイトル:Immunomedics Inc (IMMU) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C7720
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Immunomedics Inc (IMMU) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and autoimmune disorders. The company develops its candidates based on its proprietary technologies namely, ADC Linker technology and Dock-And-Lock platform. Its lead product candidate is Sacituzumab govitecan (IMMU-132) in Phase II development stage received breakthrough therapy designation from the US FDA for the treatment of patients with metastatic triple-negative breast cancer and metastatic solid cancers. Immunomedics’ other lead product candidates include Labetuzumab Govitecan (IMMU-130) and Epratuzumab. It also has other product candidates that target solid tumors, hematologic malignancies and other diseases, in various stages of clinical and pre-clinical development. The company also manufactures and commercializes diagnostic imaging product named, LeukoScan. Immunomedics is headquartered in Morris Plains, New Jersey, the US.
Immunomedics Inc Key Recent Developments
Aug 28,2018: Immunomedics Announces Participation in Upcoming Healthcare Conferences
Aug 23,2018: Immunomedics announces fourth quarter and fiscal year 2018 results and provides corporate update
May 09,2018: Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update
Apr 09,2018: Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer
Feb 08,2018: Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Immunomedics Inc – Key Facts 6
Immunomedics Inc – Key Employees 7
Immunomedics Inc – Key Employee Biographies 8
Immunomedics Inc – Major Products and Services 9
Immunomedics Inc – History 10
Immunomedics Inc – Company Statement 13
Immunomedics Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Company Overview 16
Immunomedics Inc – Business Description 17
Immunomedics Inc – Corporate Strategy 18
Immunomedics Inc – SWOT Analysis 19
SWOT Analysis – Overview 19
Immunomedics Inc – Strengths 19
Immunomedics Inc – Weaknesses 20
Immunomedics Inc – Opportunities 21
Immunomedics Inc – Threats 22
Immunomedics Inc – Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios – Capital Market Ratios 24
Financial Ratios – Annual Ratios 25
Performance Chart 27
Financial Performance 27
Financial Ratios – Interim Ratios 28
Financial Ratios – Ratio Charts 29
Section 4 – Company’s Lifesciences Financial Deals and Alliances 30
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
Immunomedics Inc, Recent Deals Summary 32
Section 5 – Company’s Recent Developments 33
Aug 28, 2018: Immunomedics Announces Participation in Upcoming Healthcare Conferences 33
Aug 23, 2018: Immunomedics announces fourth quarter and fiscal year 2018 results and provides corporate update 34
May 09, 2018: Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update 36
Apr 09, 2018: Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer 38
Feb 08, 2018: Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update 39
Nov 09, 2017: Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update 41
Aug 16, 2017: Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline 43
May 10, 2017: Immunomedics Announces Third Quarter Fiscal 2017 Results And Clinical Program Developments 45
May 05, 2017: Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value 47
Feb 21, 2017: Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws 50
Section 6 – Appendix 51
Methodology 51
Ratio Definitions 51
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Tables
Immunomedics Inc, Key Facts 6
Immunomedics Inc, Key Employees 7
Immunomedics Inc, Key Employee Biographies 8
Immunomedics Inc, Major Products and Services 9
Immunomedics Inc, History 10
Immunomedics Inc, Subsidiaries 15
Immunomedics Inc, Key Competitors 23
Immunomedics Inc, Ratios based on current share price 24
Immunomedics Inc, Annual Ratios 25
Immunomedics Inc, Annual Ratios (Cont...1) 26
Immunomedics Inc, Interim Ratios 28
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
Immunomedics Inc, Recent Deals Summary 32
Currency Codes 51
Capital Market Ratios 51
Equity Ratios 52
Profitability Ratios 52
Cost Ratios 53
Liquidity Ratios 53
Leverage Ratios 54
Efficiency Ratios 54
List of Figures
Immunomedics Inc, Performance Chart (2014 - 2018) 27
Immunomedics Inc, Ratio Charts 29
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 31